[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Progressive Multifocal Leukoencephalopathy Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 40 pages | ID: PDC6687BF30FEN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Progressive Multifocal Leukoencephalopathy Drug pipeline report- 2020 is an annual R&D review of Progressive Multifocal Leukoencephalopathy pipeline candidates. The report presents the current status of all major Progressive Multifocal Leukoencephalopathy therapeutic compounds. Detailed insights into Progressive Multifocal Leukoencephalopathy pipeline development, current status, companies, drug profiles and Progressive Multifocal Leukoencephalopathy preclinical and clinical trials are included.

2020 Progressive Multifocal Leukoencephalopathy Pipeline Market Insights
Progressive Multifocal Leukoencephalopathy disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Progressive Multifocal Leukoencephalopathy therapies, pipeline by phase and others are included.

Progressive Multifocal Leukoencephalopathy pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Progressive Multifocal Leukoencephalopathy Therapeutic Drug candidates
Both active and inactive Progressive Multifocal Leukoencephalopathy pipeline drug candidates are included in the report

Progressive Multifocal Leukoencephalopathy Clinical Trials and preclinical Studies
Progressive Multifocal Leukoencephalopathy In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Progressive Multifocal Leukoencephalopathy pipeline market developments
Progressive Multifocal Leukoencephalopathy Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Progressive Multifocal Leukoencephalopathy pipeline companies in active development
The report analyzes Progressive Multifocal Leukoencephalopathy pipeline of the below companies-

Atara Biotherapeutics Inc, Excision BioTherapeutics Inc, Forge Life Science LLC, Inhibikase Therapeutics Inc, Neurimmune Holding AG, Neuway Pharma GmbH, Pomona Ricerca SRL, Vir Biotechnology Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
8 Companies investing in Progressive Multifocal Leukoencephalopathy pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Progressive Multifocal Leukoencephalopathy pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE MARKET INSIGHTS, 2020

1.1 Progressive Multifocal Leukoencephalopathy Disease Overview
1.2 Progressive Multifocal Leukoencephalopathy Drug Pipeline Snapshot, 2020
  1.2.1 Progressive Multifocal Leukoencephalopathy Pipeline Drugs by Phase
  1.2.2 Progressive Multifocal Leukoencephalopathy Pipeline Drugs by Company
  1.2.3 Progressive Multifocal Leukoencephalopathy Pipeline Drugs by Mechanism of Action
  1.2.4 Progressive Multifocal Leukoencephalopathy Pipeline Drugs by Route of Administration

2. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY COMPANY WISE PIPELINE DETAILS

Atara Biotherapeutics Inc Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Excision BioTherapeutics Inc Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Forge Life Science LLC Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Inhibikase Therapeutics Inc Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Neurimmune Holding AG Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Neuway Pharma GmbH Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Pomona Ricerca SRL Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vir Biotechnology Inc Progressive Multifocal Leukoencephalopathy Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications